Cytek Biosciences expects FY2024 revenue $200-201M, 4% growth; Q4 rev up 11-13% QoQ

Cytek Biosciences, Inc.

Full-year 2024 revenue expected $200-201M, up 4% from $193M in 2023; ~$1M negative FX impact.
Q4 2024 revenue $57-58M, 11-13% sequential growth, down 2% to flat YoY; FX reduced Q4 by ~$1.5M.
CEO cites strong APAC and Rest of World growth, offset by order delays and USD strength.
Preliminary results unaudited; full earnings and 2025 guidance expected late February 2025.
Company to present at J.P. Morgan Healthcare Conference on January 16, 2025 in San Francisco.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.